Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLLR3: FCG vs BG in Relapsed/Refractory CLL
NCT02320383Phase 2Unknown
- Sponsor
- München Klinik
- Start
- Nov 2014
- Primary completion
- Dec 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of obinutuzumab in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by München Klinik. Primary endpoint: Overall Response Rate. Status: unknown.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02320383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320383.